|
Patient
|
Baseline evaluation
|
After treatment
|
|---|
| |
ER, %
|
PgR, %
|
HER2, % (score)
|
First assessment
|
Time A
|
Chemotherapy
|
Time B
|
Second assessment
|
ER, %
|
PgR, %
|
HER2, % (score)
|
HT
|
Clinical response
|
|---|
|
1
|
0
|
0
|
80 (3+)
|
Skin
|
20
|
Paclitaxel
|
9
|
Skin
|
10
|
0
|
70 (3+)
|
No
|
PR
|
|
2
|
0
|
0
|
70 (3+)
|
Pleura
|
87
|
Paclitaxel
|
11
|
Pleura
|
0
|
0
|
75 (3+)
|
No
|
SD
|
|
3
|
0
|
0
|
90 (3+)
|
Skin
|
8
|
Nonea
|
4
|
Skin
|
0
|
0
|
90 (3+)
|
No
|
PR
|
|
4
|
0
|
0
|
40 (3+)
|
Skin
|
31
|
Paclitaxel
|
9
|
Skin
|
0
|
0
|
90 (3+)
|
No
|
PD
|
|
5
|
0
|
0
|
90 (3+)
|
Liver
|
5
|
Nonea
|
12
|
Ovary
|
50
|
40
|
80 (3+)
|
Yes
|
PD
|
|
6
|
0
|
0
|
95 (3+)
|
Breast
|
2
|
Paclitaxel
|
37
|
Breast
|
20
|
0
|
90 (3+)
|
Yes
|
PR
|
|
7
|
0
|
0
|
80 (3+)
|
Skin
|
64
|
Nonea
|
4
|
Skin
|
0
|
0
|
95 (3+)
|
No
|
PR
|
|
8
|
0
|
0
|
90 (3+)
|
Lung
|
2
|
Paclitaxel
|
4
|
Skin
|
0
|
0
|
90 (3+)
|
No
|
SD
|
|
9
|
0
|
0
|
80 (3+)
|
Skin
|
51
|
Paclitaxel
|
22
|
Skin
|
0
|
0
|
40 (2+)
|
No
|
PR
|
|
10
|
0
|
0
|
90 (3+)
|
Skin
|
17
|
Vinorelbine
|
3
|
Skin
|
0
|
0
|
90 (3+)
|
No
|
PR
|
- The table shows the evaluation of patients' characteristics at baseline with the site of disease at which the biological characteristics were evaluated, and after treatment with trastuzumab with the site of disease at which the biological characteristics were reassessed. ER, estrogen receptor; first assessment, site of disease where ER, PgR and HER2 were evaluated at baseline; HT, hormonal treatment; PgR, progesterone receptor; second assessment, site of disease where ER, PgR and HER2 were reassessed; time A, time elapsed between first assessment and treatment start (weeks); time B, time elapsed between trastuzumab start and second assessment (weeks). PD, progressive disease. SD, stable disease. PR, partial response.
-
aPaclitaxel was introduced after progression to trastuzumab alone.
